The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Next generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Matrix metalloproteinases as modulators of inflammation and innate immunity
Parks, W. C., Wilson, C. L., & López-Boado, Y. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1418 · Cited by 1,929
Van Wart, H. E., & Birkedal-Hansen, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5578 · Cited by 1,475
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349
S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. W., Liddington, R. C., & Lipton, S. A. (2002) · Science · doi:10.1126/science.1073634 · Cited by 950
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
Directed evolution drives the next generation of biocatalysts
Turner, N. J. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.203 · Cited by 785
Research works printed but not linked: 212
- Brinckerhoff, 2002, Matrix metalloproteinases: a tail of a frog that became a prince, Nat. Rev. Mol. Cell Biol., 3, 207, 10.1038/nrm763 · DOI · Paper page
- Solomonov, 2016, Distinct biological events generated by ECM proteolysis by two homologous collagenases, Proc. Natl. Acad. Sci. U. S. A., 113, 10884, 10.1073/pnas.1519676113 · DOI
- Bode, 1993, Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the ‘metzincins’, FEBS Lett., 331, 134, 10.1016/0014-5793(93)80312-I · DOI · Paper page
- Gaffney, 2015, Multilevel regulation of matrix metalloproteinases in tissue homeostasis indicates their molecular specificity in vivo, Matrix Biol., 44-46, 191, 10.1016/j.matbio.2015.01.012 · DOI
- Wong, 2015, The functional maturation of a disintegrin and metalloproteinase (ADAM) 9, 10, and 17 requires processing at a newly identified proprotein convertase (PC) cleavage site, J. Biol. Chem., 290, 12135, 10.1074/jbc.M114.624072 · DOI
- Nagase, 2006, Structure and function of matrix metalloproteinases and TIMPs, Cardiovasc. Res., 69, 562, 10.1016/j.cardiores.2005.12.002 · DOI · Paper page
- Murphy, 1994, Regulation of matrix metalloproteinase activity, Ann. N. Y. Acad. Sci., 732, 31, 10.1111/j.1749-6632.1994.tb24722.x · DOI · Paper page
- Mignatti, 1996, Plasminogen activators and matrix metalloproteinases in angiogenesis, Enzyme Protein, 49, 117, 10.1159/000468621 · DOI · Paper page
- Okamoto, 2001, Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation, J. Biol. Chem., 276, 29596, 10.1074/jbc.M102417200 · DOI · Paper page
- Fu, 2008, Activation and silencing of matrix metalloproteinases, Semin. Cell Dev. Biol., 19, 2, 10.1016/j.semcdb.2007.06.005 · DOI
- Martin, 2007, The other side of MMPs: protective roles in tumor progression, Cancer Metastasis Rev., 26, 717, 10.1007/s10555-007-9089-4 · DOI · Paper page
- Gialeli, 2011, Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting, FEBS J., 278, 16, 10.1111/j.1742-4658.2010.07919.x · DOI · Paper page
- Fingleton, 2008, MMPs as therapeutic targets—still a viable option?, Semin. Cell Dev. Biol., 19, 61, 10.1016/j.semcdb.2007.06.006 · DOI · Paper page
- Taraboletti, 1995, Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases, J. Natl. Cancer Inst., 87, 293, 10.1093/jnci/87.4.293 · DOI · Paper page
- Wada, 2003, Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition, Clin. Exp. Metastasis, 20, 431, 10.1023/A:1025453500148 · DOI
- Westwood, 2009, Characterization of fibrodysplasia in the dog following inhibition of metalloproteinases, Toxicol. Pathol., 37, 860, 10.1177/0192623309347909 · DOI
- Marshall, 2015, Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer, PLoS One, 10, 10.1371/journal.pone.0127063 · DOI · Paper page
- De Meijer, 2010, Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice, PLoS One, 5, 10.1371/journal.pone.0011256 · DOI
- Gaublomme, 2014, Matrix metalloproteinase 2 and membrane type 1 matrix metalloproteinase co-regulate axonal outgrowth of mouse retinal ganglion cells, J. Neurochem., 129, 966, 10.1111/jnc.12703 · DOI
- Bode, 2003, Structural basis of matrix metalloproteinase function, Biochem. Soc. Symp., 1
- Huang, 1996, Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli, FEBS Lett., 384, 155, 10.1016/0014-5793(96)00304-3 · DOI
- Murphy, 1991, The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity, Biochemistry, 30, 8097, 10.1021/bi00247a001 · DOI · Paper page
- de Bruyn, 2016, The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases, Crit. Rev. Biochem. Mol. Biol., 51, 295, 10.1080/10409238.2016.1199535 · DOI
- O'Sullivan, 2015, Matrix metalloproteinases in inflammatory bowel disease: an update, Mediat. Inflamm., 964131, 10.1155/2015/964131 · DOI · Paper page
- Ricard-Blum, 2016, Matricryptins network with matricellular receptors at the surface of endothelial and tumor cells, Front. Pharmacol., 7, 11, 10.3389/fphar.2016.00011 · DOI
- Liu, 2001, Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth, Cancer Res., 61, 1022
- Weathington, 2006, A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation, Nat. Med., 12, 317, 10.1038/nm1361 · DOI · Paper page
- Feng, 2015, Collagen-derived N-acetylated proline-glycine-proline in intervertebral discs modulates CXCR1/2 expression and activation in cartilage endplate stem cells to induce migration and differentiation toward a pro-inflammatory phenotype, Stem Cells, 33, 3558, 10.1002/stem.2200 · DOI
- Hill, 2016, N-acetyl proline-glycine-proline: implications for neurological disorders., Neural Regen. Res., 11, 898, 10.4103/1673-5374.184478 · DOI
- Feng, 2017, The matrikine N-acetylated proline-glycine-proline induces premature senescence of nucleus pulposus cells via CXCR1-dependent ROS accumulation and DNA damage and reinforces the destructive effect of these cells on homeostasis of intervertebral discs, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis., 1863, 220, 10.1016/j.bbadis.2016.10.011 · DOI
- Heinz, 2010, Degradation of tropoelastin by matrix metalloproteinases—cleavage site specificities and release of matrikines, FEBS J., 277, 1939, 10.1111/j.1742-4658.2010.07616.x · DOI
- Asundi, 2003, Matrix metalloproteinase-dependent shedding of syndecan-3, a transmembrane heparan sulfate proteoglycan, in Schwann cells, J. Neurosci. Res., 73, 593, 10.1002/jnr.10699 · doi:10.1002/jnr.10699
- Choi, 2015, Proteoglycans in health and disease: the multiple roles of syndecan shedding; the matrix metalloproteinase-7 regulates the extracellular shedding of syndecan-2 from colon cancer cells, Oncotarget, 6, 3874, 10.18632/oncotarget.2885 · doi:10.18632/oncotarget.2885
- Arolas, 2012, Structural basis for the sheddase function of human meprin β metalloproteinase at the plasma membrane, Proc. Natl. Acad. Sci., 109, 16131, 10.1073/pnas.1211076109 · DOI
- Choi, 2010, The matrix metalloproteinase-7 regulates the extracellular shedding of syndecan-2 from colon cancer cells, Biochem. Biophys. Res. Commun., 417, 1260, 10.1016/j.bbrc.2011.12.120 · DOI
- Kwon, 2014, Interleukin-1α promotes extracellular shedding of syndecan-2 via induction of matrix metalloproteinase-7 expression, Biochem. Biophys. Res. Commun., 446, 487, 10.1016/j.bbrc.2014.02.142 · doi:10.1016/j.bbrc.2014.02.142
- Fears, 2006, Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells, J. Biol. Chem., 281, 14533, 10.1074/jbc.C600075200 · DOI
- Gaggar, 2008, A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic, J. Immunol., 180, 5662, 10.4049/jimmunol.180.8.5662 · DOI · Paper page
- Rebustini, 2009, Inflammation MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis, Dev. Cell, 17, 482, 10.1016/j.devcel.2009.07.016 · DOI
- Lindsey, 2015, A novel collagen matricryptin reduces left ventricular dilation post-myocardial infarction by promoting scar formation and angiogenesis., J. Am. Coll. Cardiol., 66, 1364, 10.1016/j.jacc.2015.07.035 · DOI · Paper page
- Xu, 2001, Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo, J. Cell Biol., 154, 1069, 10.1083/jcb.200103111 · DOI · Paper page
- Koshikawa, 2000, Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5, J. Cell Biol., 148, 615, 10.1083/jcb.148.3.615 · DOI · Paper page
- Pirilä, 2003, Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration, Biochem. Biophys. Res. Commun., 303, 1012, 10.1016/S0006-291X(03)00452-2 · DOI
- Mañes, 1997, Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3, J. Biol. Chem., 272, 25706, 10.1074/jbc.272.41.25706 · DOI · Paper page
- Miyamoto, 2004, Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3, Cancer Res., 64, 665, 10.1158/0008-5472.CAN-03-1916 · DOI
- Fowlkes, 1994, Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures, J. Biol. Chem., 269, 10.1016/S0021-9258(18)47310-3 · DOI · Paper page
- Rajah, 1999, Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle, Am. J. Respir. Cell Mol. Biol., 20, 199, 10.1165/ajrcmb.20.2.3148 · doi:10.1165/ajrcmb.20.2.3148
- Fowlkes, 1999, MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth, Ann. N. Y. Acad. Sci., 878, 696, 10.1111/j.1749-6632.1999.tb07765.x · DOI
- Coppock, 2004, Matrix metalloprotease-3 and -9 proteolyze insulin-like growth factor-binding protein-1, Biol. Reprod., 71, 438, 10.1095/biolreprod.103.023101 · DOI
- Imai, 1997, Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture, J. Clin. Invest., 100, 2596, 10.1172/JCI119803 · DOI
- Zhang, 2004, Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals, J. Biol. Chem., 279, 19683, 10.1074/jbc.M313145200 · DOI
- Chattopadhyay, 2009, MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway, Glia, 57, 1316, 10.1002/glia.20851 · DOI
- Samani, 2009, The role of the IGF system in cancer growth and metastasis: overview and recent insights, Endocr. Rev., 28, 20, 10.1210/er.2006-0001 · DOI · Paper page
- Yu, 2000, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis, Genes Dev., 14, 163, 10.1101/gad.14.2.163 · DOI · Paper page
- Dangelo, 2001, Activation of transforming growth factor beta in chondrocytes undergoing endochondral ossification, J. Bone Miner. Res., 16, 2339, 10.1359/jbmr.2001.16.12.2339 · DOI
- Mu, 2002, The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1, J. Cell Biol., 157, 493, 10.1083/jcb.200109100 · DOI · Paper page
- Khan, 2016, The role of proteases in transforming growth factor-β activation, Cell Tissue Res., 365, 657, 10.1007/s00441-016-2474-y · DOI
- Velasco-Loyden, 2004, The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1, J. Biol. Chem., 279, 7721, 10.1074/jbc.M306499200 · DOI
- Finnson, 2013, Dynamics of transforming growth factor beta signaling in wound healing and scarring, Adv. Wound Care, 2, 195, 10.1089/wound.2013.0429 · DOI · Paper page
- Colnot, 2003, Altered fracture repair in the absence of MMP9, Development, 130, 4123, 10.1242/dev.00559 · DOI · Paper page
- Lee, 2005, Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors, J. Cell Biol., 169, 681, 10.1083/jcb.200409115 · DOI · Paper page
- Ito, 2007, The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells, Oncogene, 26, 7194, 10.1038/sj.onc.1210535 · DOI
- Munaut, 2003, Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas, Int. J. Cancer, 106, 848, 10.1002/ijc.11313 · DOI · Paper page
- Eisenach, 2010, MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src, J. Cell Sci., 123, 4182, 10.1242/jcs.062711 · DOI
- Dean, 2007, Mol. Cell. Biol., 27, 8454, 10.1128/MCB.00821-07 · DOI · Paper page
- Héroult, 2004, Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis, Oncogene, 23, 1745, 10.1038/sj.onc.1206879 · DOI
- Hashimoto, 2002, Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165, J. Biol. Chem., 277, 36288, 10.1074/jbc.M201674200 · DOI · Paper page
- Ito, 1996, Degradation of interleukin 1, J. Biol. Chem., 271, 14657, 10.1074/jbc.271.25.14657 · DOI · Paper page
- Schönbeck, 1998, Generation of biologically active IL-1 beta bymatrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 betaprocessing, J. Immunol., 161, 3340, 10.4049/jimmunol.161.7.3340 · DOI · Paper page
- Tester, 2007, LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity, PLoS One, 2, 10.1371/journal.pone.0000312 · DOI · Paper page
- Le Quément, 2008, MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cells, Am. J. Phys. Lung Cell. Mol. Phys., 294, L1076
- Van den Steen, 2000, Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO- alpha and leaves RANTES and MCP-2 intact, Blood, 96, 2673, 10.1182/blood.V96.8.2673 · DOI · Paper page
- Nelissen, 2003, Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy, Brain, 126, 1371, 10.1093/brain/awg129 · DOI
- Westermann, 2011, Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy, Circulation, 124, 2082, 10.1161/CIRCULATIONAHA.111.035964 · DOI
- Vassalli, 1992, The pathophysiology of tumor necrosis factors, Annu. Rev. Immunol., 10, 411, 10.1146/annurev.iy.10.040192.002211 · doi:10.1146/annurev.iy.10.040192.002211 · Paper page
- Gearing, 1994, Processing of tumour necrosis factor-alpha precursor by metalloproteinases, Nature, 370, 555, 10.1038/370555a0 · DOI · Paper page
- Chandler, 1996, Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alfa fusion protein, Biochem. Biophys. Res. Commun., 228, 421, 10.1006/bbrc.1996.1677 · DOI · Paper page
- d'Ortho, 1997, Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases, Eur. J. Biochem., 250, 751, 10.1111/j.1432-1033.1997.00751.x · DOI · Paper page
- Tam, 2004, Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates, Proc. Natl. Acad. Sci. U. S. A., 101, 6917, 10.1073/pnas.0305862101 · DOI · Paper page
- Vandenbroucke, 2013, Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF, EMBO Mol. Med., 5, 1000, 10.1002/emmm.201202100 · DOI
- English, 2000, Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2, J. Biol. Chem., 275, 14046, 10.1074/jbc.275.19.14046 · DOI · Paper page
- Jin, 2008, Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization, Bone Marrow Transplant., 42, 581, 10.1038/bmt.2008.222 · DOI
- Abdul-Muneer, 2017, Traumatic brain injury induced matrix metalloproteinase2 cleaves CXCL12α (stromal cell derived factor 1α) and causes neurodegeneration, Brain Behav. Immun., 59, 190, 10.1016/j.bbi.2016.09.002 · DOI
- McGuire, 2003, Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium, Am. J. Pathol., 162, 1831, 10.1016/S0002-9440(10)64318-0 · DOI · Paper page
- Noë, 2001, Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1, J. Cell Sci., 114, 111, 10.1242/jcs.114.1.111 · DOI · Paper page
- Lochter, 1997, Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells, J. Cell Biol., 139, 1861, 10.1083/jcb.139.7.1861 · DOI · Paper page
- Cavallaro, 2004, Cell adhesion and signaling by cadherins and Ig-CAMs in cancer, Nat. Rev. Cancer, 4, 118, 10.1038/nrc1276 · DOI · Paper page
- Nawrocki-Raby, 2003, Upregulation of MMPs by soluble E-cadherin in human lung tumor cells, Int. J. Cancer, 105, 790, 10.1002/ijc.11168 · DOI
- Deryugina, 2002, Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase, J. Biol. Chem., 277, 9749, 10.1074/jbc.M110269200 · DOI · Paper page
- Abdel-Ghany, 2001, The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis, J. Biol. Chem., 276, 25438, 10.1074/jbc.M100478200 · DOI
- Kajita, 2001, Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration, J. Cell Biol., 153, 893, 10.1083/jcb.153.5.893 · DOI · Paper page
- Marrero-Diaz, 2009, Polarized MT1-MMP-CD44 interaction and CD44 cleavage during cell retraction reveal an essential role for MT1-MMP in CD44-mediated invasion, Cell Motil. Cytoskeleton, 66, 48, 10.1002/cm.20325 · DOI
- Chetty, 2012, MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells, Cell. Signal., 24, 549, 10.1016/j.cellsig.2011.10.008 · DOI
- Iyer, 2015, Early matrix metalloproteinase-12 inhibition worsens post-myocardial infarction cardiac dysfunction by delaying inflammation resolution, Int. J. Cardiol., 185, 10.1016/j.ijcard.2015.03.054 · DOI
- Jiang, 2015, CD44 regulates pancreatic cancer invasion through MT1-MMP, Mol. Cancer Res., 13, 9, 10.1158/1541-7786.MCR-14-0076 · DOI
- Yu, 2002, CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling, Genes Dev., 16, 307, 10.1101/gad.925702 · DOI · Paper page
- Levi, 1996, Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1, Proc. Natl. Acad. Sci. U. S. A., 93, 7069, 10.1073/pnas.93.14.7069 · DOI · Paper page
- Talmi-Frank, 2016, Extracellular matrix proteolysis by MT1-MMP contributes to influenza-related tissue damage and mortality., Cell Host Microbe, 20, 458, 10.1016/j.chom.2016.09.005 · DOI
- Houghton, 2009, Macrophage elastase kills bacteria within murine macrophages, Nature, 460, 637, 10.1038/nature08181 · DOI · Paper page
- Elkington, 2011, Matrix metalloproteinases in tuberculosis, Eur. Respir. J., 38, 456, 10.1183/09031936.00015411 · DOI
- Sathyamoorthy, 2015, Membrane type 1 matrix metalloproteinase regulates monocyte migration and collagen destruction in tuberculosis, J. Immunol., 195, 882, 10.4049/jimmunol.1403110 · DOI
- Rosenberg, 2002, Matrix metalloproteinases in neuroinflammation, Glia, 39, 279, 10.1002/glia.10108 · DOI · Paper page
- Wang, 2014, Matrix metalloproteinases and their multiple roles in Alzheimer's disease, Biomed. Res. Int., 2014, 908636
- Lukaszewicz-Zajac, 2014, Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS), J. Neural. Transm. (Vienna), 121, 1387, 10.1007/s00702-014-1205-3 · DOI
- Rosenberg, 2002, Matrix metalloproteinases and neuroinflammation in multiple sclerosis, Neuroscientist, 8, 586, 10.1177/1073858402238517 · DOI
- Noble, 2002, Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events, J. Neurosci., 22, 7526, 10.1523/JNEUROSCI.22-17-07526.2002 · DOI · Paper page
- Zhao, 2006, Role of matrix metalloproteinases in delayed cortical responses after stroke, Nat. Med., 12, 441, 10.1038/nm1387 · DOI · Paper page
- Lakhan, 2012, Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets, Pain Res. Treat., 2012, 952906
- Ahmed, 2011, Novel targets for spinal cord injury related neuropathic pain, Ann. Neurosci., 18, 162, 10.5214/ans.0972.7531.1118413 · DOI
- Ji, 2009, Matrix metalloprotease regulation of neuropathic pain, Trends Pharmacol. Sci., 30, 336, 10.1016/j.tips.2009.04.002 · DOI · Paper page
- Fields, 2015, New strategies for targeting matrix metalloproteinases, Matrix Biol., 44-46, 239, 10.1016/j.matbio.2015.01.002 · DOI · Paper page
- Kleifeld, 2001, X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. Comparison with the latent and active forms of the enzyme, J. Biol. Chem., 276, 17125, 10.1074/jbc.M011604200 · DOI
- Pirard, 2007, Insight into the structural determinants for selective inhibition of matrix metalloproteinases, Drug Discov. Today, 12, 640, 10.1016/j.drudis.2007.06.003 · DOI
- Overall, 2006, Towards third generation matrix metalloproteinase inhibitors for cancer therapy, Br. J. Cancer, 94, 941, 10.1038/sj.bjc.6603043 · DOI · Paper page
- Devel, 2006, Development of selective inhibitors and substrate of matrix metalloproteinase-12, J. Biol. Chem., 281, 11152, 10.1074/jbc.M600222200 · DOI
- Devel, 2010, Third generation of matrix metalloprotease inhibitors: gain in selectivity by targeting the depth of the S1′ cavity, Biochimie, 92, 1501, 10.1016/j.biochi.2010.07.017 · DOI
- Rouanet-Mehouas, 2017, Zinc-metalloproteinase inhibitors: evaluation of the complex role played by the zinc-binding group on potency and selectivity, J. Med. Chem., 60, 403, 10.1021/acs.jmedchem.6b01420 · DOI
- Lopez-Otin, 2009, Protective roles of matrix metalloproteinases: from mouse models to human cancer, Cell Cycle (Georgetown, Tex), 8, 3657, 10.4161/cc.8.22.9956 · DOI
- Overall, 2006, Tumour microenvironment — opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy, Nat. Rev. Cancer, 6, 227, 10.1038/nrc1821 · DOI · Paper page
- Sela-Passwell, 2010, Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition?, Biochim. Biophys. Acta, 1803, 29, 10.1016/j.bbamcr.2009.04.010 · DOI
- Sela-Passwell, 2010, Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition?, BBA Mol. Cell Res., 1803, 29
- Bhowmick, 2015, Matrix metalloproteinase inhibition by heterotrimeric triple-helical peptide transition state analogues, Chembiochem, 16, 1084, 10.1002/cbic.201402716 · DOI
- Deu, 2012, New approaches for dissecting protease functions to improve probe development and drug discovery, Nat. Struct. Mol. Biol., 19, 9, 10.1038/nsmb.2203 · DOI · Paper page
- Turk, 2006, Targeting proteases: successes, failures and future prospects, Nat. Rev. Drug Discov., 5, 785, 10.1038/nrd2092 · DOI · Paper page
- Udi, 2013, Unraveling hidden regulatory sites in structurally homologous metalloproteases, J. Mol. Biol., 425, 2330, 10.1016/j.jmb.2013.04.009 · DOI
- Laskowski, 2009, The structural basis of allosteric regulation in proteins, FEBS Lett., 583, 1692, 10.1016/j.febslet.2009.03.019 · DOI · Paper page
- Wu, 2007, Structural insight into distinct mechanisms of protease inhibition by antibodies, Proc. Natl. Acad. Sci. U. S. A., 104, 19784, 10.1073/pnas.0708251104 · DOI
- Sela-Passwell, 2012, Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential, Nat. Med., 18, 143, 10.1038/nm.2582 · DOI
- Chothia, 1987, Canonical structures for the hypervariable regions of immunoglobulins, J. Mol. Biol., 196, 901, 10.1016/0022-2836(87)90412-8 · DOI · Paper page
- MacCallum, 1996, Antibody-antigen interactions: contact analysis and binding site topography, J. Mol. Biol., 262, 732, 10.1006/jmbi.1996.0548 · DOI · Paper page
- Garg, 2009, Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis, Am. J. Physiol. Gastrointest. Liver, 296, G175, 10.1152/ajpgi.90454.2008 · DOI
- Paemen, 1995, Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity, Eur. J. Biochem., 234, 759, 10.1111/j.1432-1033.1995.759_a.x · DOI
- Hu, 2004, Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody, Biochem. Pharmacol., 67, 1001, 10.1016/j.bcp.2003.10.030 · DOI
- Martens, 2007, A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains, Biochim. Biophys. Acta, 1770, 178, 10.1016/j.bbagen.2006.10.012 · DOI
- Pruijt, 1999, Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9), Proc. Natl. Acad. Sci. U. S. A., 96, 10863, 10.1073/pnas.96.19.10863 · DOI · Paper page
- Galvez, 2001, Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling, J. Biol. Chem., 276, 37491, 10.1074/jbc.M104094200 · DOI · Paper page
- Talmi-Frank, 2016, Extracellular matrix proteolysis by MT1-MMP contributes to influenza-related tissue damage and mortality, Cell Host Microbe, 20, 458, 10.1016/j.chom.2016.09.005 · DOI
- Udi, 2015, Inhibition mechanism of membrane metalloprotease by an exosite-swiveling conformational antibody, Structure, 23, 104, 10.1016/j.str.2014.10.012 · DOI
- Ingvarsen, 2013, Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis, J. Biol. Chem., 288, 10195, 10.1074/jbc.M112.447169 · DOI
- Shiryaev, 2013, A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP, Oncogene, 2
- Butler, 1998, The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study, J. Biol. Chem., 273, 871, 10.1074/jbc.273.2.871 · DOI · Paper page
- Knauper, 1996, Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme, J. Biol. Chem., 271, 17124
- Strongin, 1995, Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease, J. Biol. Chem., 270, 5331, 10.1074/jbc.270.10.5331 · DOI · Paper page
- Detry, 2012, Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase, Blood, 119, 5048, 10.1182/blood-2011-12-400267 · DOI
- Nam, 2016, Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries, Proc. Natl. Acad. Sci. U. S. A., 113, 14970, 10.1073/pnas.1609375114 · DOI
- Sircar, 2011, Analysis and modeling of the variable region of camelid single-domain antibodies, J. Immunol., 186, 6357, 10.4049/jimmunol.1100116 · DOI · Paper page
- Moss, 2007, The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events, J. Biol. Chem., 282, 35712, 10.1074/jbc.M703231200 · DOI
- Wong, 2016, Harnessing the natural inhibitory domain to control TNFalpha Converting Enzyme (TACE) activity in vivo, Sci Rep, 6, 35598, 10.1038/srep35598 · DOI
- Moss, 2008, Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis, Nat. Clin. Pract. Rheumatol., 4, 300, 10.1038/ncprheum0797 · DOI · Paper page
- Feldmann, 1996, Role of cytokines in rheumatoid arthritis, Annu. Rev. Immunol., 14, 397, 10.1146/annurev.immunol.14.1.397 · DOI · Paper page
- Papadakis, 2000, Role of cytokines in the pathogenesis of inflammatory bowel disease, Annu. Rev. Med., 51, 289, 10.1146/annurev.med.51.1.289 · DOI · Paper page
- Kefaloyianni, 2016, ADAM17 substrate release in proximal tubule drives kidney fibrosis, JCI Insight, 1, 10.1172/jci.insight.87023 · DOI
- Gur-Cohen, 2015, PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells, Nat. Med., 21, 1307, 10.1038/nm.3960 · DOI
- Said, 2014, The role of matrix metalloproteinases in colorectal cancer, Cancer, 6, 366, 10.3390/cancers6010366 · DOI · Paper page
- Ding, 2011, Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization, Cell, 147, 539, 10.1016/j.cell.2011.10.003 · DOI · Paper page
- Antoni, 2013, Crystallization of bi-functional ligand protein complexes, J. Struct. Biol., 182, 246, 10.1016/j.jsb.2013.03.015 · DOI
- Morgunova, 1999, Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed, Science, 284, 1667, 10.1126/science.284.5420.1667 · DOI · Paper page
- Lee, 2003, Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase, J. Biol. Chem., 278, 40224, 10.1074/jbc.M305678200 · DOI
- Chao, 2006, Isolating and engineering human antibodies using yeast surface display, Nat. Protoc., 1, 755, 10.1038/nprot.2006.94 · DOI · Paper page
- Whitehead, 2012, Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing, Nat. Biotechnol., 30, 543, 10.1038/nbt.2214 · DOI · Paper page
- Levin, 2013, Employing directed evolution for the functional analysis of multi-specific proteins, Bioorg. Med. Chem., 21, 3511, 10.1016/j.bmc.2013.04.052 · DOI
- Aharoni, 2004, Directed evolution of recombinant serum paraoxonase (PON) variants, Discov. Med., 4, 120
- Aharoni, 2005, High-throughput screens and selections of enzyme-encoding genes, Curr. Opin. Chem. Biol., 9, 210, 10.1016/j.cbpa.2005.02.002 · DOI · Paper page
- Lutz, 2010, Beyond directed evolution—semi-rational protein engineering and design, Curr. Opin. Biotechnol., 21, 734, 10.1016/j.copbio.2010.08.011 · DOI · Paper page
- Kintzing, 2016, Emerging strategies for developing next-generation protein therapeutics for cancer treatment, Trends Pharmacol. Sci., 10.1016/j.tips.2016.10.005 · DOI · Paper page
- Bahudhanapati, 2011, Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2) identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)), J. Biol. Chem., 286, 31761, 10.1074/jbc.M111.253328 · DOI
- Sharabi, 2014, Affinity-and specificity-enhancing mutations are frequent in multispecific interactions between TIMP2 and MMPs, PLoS One, 9, 10.1371/journal.pone.0093712 · DOI
- Rabinovich, 2016, Identifying residues that determine SCF molecular-level interactions through a combination of experimental and in silico analyses, J. Mol. Biol.
- Boder, 2000, Yeast surface display for directed evolution of protein expression, affinity, and stability, Methods Enzymol., 328, 430, 10.1016/S0076-6879(00)28410-3 · DOI · Paper page
- Roodveldt, 2005, Directed evolution of proteins for heterologous expression and stability, Curr. Opin. Struct. Biol., 15, 50, 10.1016/j.sbi.2005.01.001 · DOI
- Amar, 2012, The transition of human estrogen sulfotransferase from generalist to specialist using directed enzyme evolution, J. Mol. Biol., 416, 21, 10.1016/j.jmb.2011.12.013 · DOI
- Xia, 2002, Directed evolution of novel polymerase activities: mutation of a DNA polymerase into an efficient RNA polymerase, Proc. Natl. Acad. Sci., 99, 6597, 10.1073/pnas.102577799 · DOI
- Cathcart, 2015, Targeting matrix metalloproteinases in cancer: bringing new life to old ideas, Genes Dis., 2, 26, 10.1016/j.gendis.2014.12.002 · DOI · Paper page
- Jabaiah, 2011, Directed evolution of protease beacons that enable sensitive detection of endogenous MT1-MMP activity in tumor cell lines, Chem. Biol., 18, 392, 10.1016/j.chembiol.2010.12.017 · DOI
- Miller, 2011, Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities, Integr. Biol., 3, 422, 10.1039/C0IB00083C · DOI
- Gura, 2002, Therapeutic antibodies: magic bullets hit the target, Nature, 417, 584, 10.1038/417584a · DOI
- Sgro, 1995, Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review, Toxicology, 105, 23, 10.1016/0300-483X(95)03123-W · DOI · Paper page
- Kettleborough, 1991, Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation, Protein Eng., 4, 773, 10.1093/protein/4.7.773 · DOI · Paper page
- Holliger, 2005, Engineered antibody fragments and the rise of single domains, Nat. Biotechnol., 23, 1126, 10.1038/nbt1142 · DOI · Paper page
- Schrama, 2006, Antibody targeted drugs as cancer therapeutics, Nat. Rev. Drug Discov., 5, 147, 10.1038/nrd1957 · DOI · Paper page
- Pfaffen, 2010, Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3, Exp. Cell Res., 316, 836, 10.1016/j.yexcr.2009.11.004 · DOI
- Botkjaer, 2016, Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo, Oncotarget, 7, 16773, 10.18632/oncotarget.7780 · DOI
- Remacle, 2016, Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis, Oncotarget
- Knight, 1992, A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases, FEBS Lett., 296, 263, 10.1016/0014-5793(92)80300-6 · DOI · Paper page
- Souriau, 2003, Recombinant antibodies for cancer diagnosis and therapy, Expert. Opin. Biol. Ther., 3, 305, 10.1517/14712598.3.2.305 · DOI
- Hoet, 2005, Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity, Nat. Biotechnol., 23, 344, 10.1038/nbt1067 · DOI · Paper page
- Devy, 2009, Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis, Cancer Res., 69, 1517, 10.1158/0008-5472.CAN-08-3255 · DOI · Paper page
- Schreuder, 1993, Targeting of a heterologous protein to the cell wall of Saccharomyces cerevisiae, Yeast, 9, 399, 10.1002/yea.320090410 · DOI · Paper page
- Boder, 1997, Yeast surface display for screening combinatorial polypeptide libraries, Nat. Biotechnol., 15, 553, 10.1038/nbt0697-553 · DOI · Paper page
- Esteban, 2004, Directed evolution of soluble single-chain human class II MHC molecules, J. Mol. Biol., 340, 81, 10.1016/j.jmb.2004.04.054 · DOI
- Jones, 2006, Engineering and characterization of a stabilized α1/α2 module of the class I major histocompatibility complex product Ld, J. Biol. Chem., 281, 25734, 10.1074/jbc.M604343200 · DOI
- Shusta, 1999, Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency, J. Mol. Biol., 292, 949, 10.1006/jmbi.1999.3130 · DOI · Paper page
- Kim, 2006, Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast, Proteins Struct. Funct. Bioinf., 62, 1026, 10.1002/prot.20618 · doi:10.1002/prot.20618
- Rajpal, 2005, A general method for greatly improving the affinity of antibodies by using combinatorial libraries, Proc. Natl. Acad. Sci. U. S. A., 102, 8466, 10.1073/pnas.0503543102 · DOI
- Boder, 2000, Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity, Proc. Natl. Acad. Sci., 97, 10701, 10.1073/pnas.170297297 · DOI · Paper page
- Mehner, 2013, Engineering TIMP-1 for selective MMP inhibition and future use as a protein therapeutic, Cancer Res., 73, 5069, 10.1158/1538-7445.AM2013-5069 · doi:10.1158/1538-7445.am2013-5069
- Grossman, 2010, The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function, Biochemistry, 49, 6184, 10.1021/bi902141x · DOI · Paper page
- Meng, 1999, Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1′ residue of substrate, J. Biol. Chem., 274, 10184, 10.1074/jbc.274.15.10184 · DOI
- Nagase, 2002, Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics, Arthritis Res. Ther., 4, 1
- Berger, 2011, The molecular basis for the broad substrate specificity of human sulfotransferase 1A1, PLoS One, 6, 10.1371/journal.pone.0026794 · DOI
200 of 212 shown
Cited by
Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
Winer, A., Adams, S., & Mignatti, P. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0646 · Cited by 651
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
Fields, G. B. (2019) · Cells · doi:10.3390/cells8090984 · Cited by 299
Estrogen Effects on Wound Healing
Horng, H.-C., Chang, W.-H., Yeh, C.-C., Huang, B.-S., Chang, C.-P., Chen, Y.-J., Tsui, K.-H., & Wang, P.-H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112325 · Cited by 208
In vitro 3d cultures to model the tumor microenvironment
Fontana, F., Marzagalli, M., Sommariva, M., Gagliano, N., & Limonta, P. (2021) · Cancers · doi:10.3390/cancers13122970 · Cited by 103
Metadata
- Authors
- Levin, M., Udi, Y., Solomonov, I., & Sagi, I.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 1864
- Issue
- 11
- Pages
- 1927-1939
- ISSN
- 0167-4889 (ISSN-L)
- OpenAlex
- W2659780310
- Cited by
- 186
- References
- 13
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- Funders
- European Research Council (DLV-695437)
- Minerva Foundation (712592-01)
- Israel Science Foundation (1226/13)
- United States - Israel Binational Science Foundation (712506-01)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Next generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects. https://app.cochat.ai/papers/10.1016/j.bbamcr.2017.06.009
- The paper
- Levin, M., Udi, Y., Solomonov, I., & Sagi, I. (2017). Next generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. https://doi.org/10.1016/j.bbamcr.2017.06.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.